Protocol Summaries: cilomilast
| GSK Study ID |
Phase | Title | Status |
|---|---|---|---|
| CIL103657 | Phase 3 | A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) | Completed |